Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06796361
PHASE1

Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness

Sponsor: University Hospital, Basel, Switzerland

View on ClinicalTrials.gov

Summary

Psilocybin (active compound of "magic mushrooms") is a prototypical psychedelic substance that acts via agonism on serotonin (5-HT) 2A receptors. Psilocybin is rapidly metabolized into its active metabolite psilocin. Psilocybin is currently under investigation as potential treatment for various neuropsychiatric disorders. Psilocybin is also widely used for recreational purposes and as research tool in neuroscience. Besides its current clinical development, a clear characterization of the dose-response relationship of psilocybin is lacking. With the present study the investigators aim to close this knowledge gap by administering low (5mg) to high (40mg) single doses of psilocybin to healthy participants. Besides its agonism on 5-HT2A receptors, psilocin also binds to other receptors and inhibits serotonin transporters (SERT). To this data only few studies have investigated these effects and never at a high dose.

Official title: Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)

Key Details

Gender

All

Age Range

25 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

16

Start Date

2025-04-21

Completion Date

2026-08

Last Updated

2025-05-28

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

Ketanserin 40mg plus Psilocybin 40mg

40mg Ketanserin oral will be administered followed by 40mg Psilocybin.

DRUG

40mg Psilocybin

Placebo oral followed by 40mg Psilocybin one hour later.

DRUG

20mg Psilocybin

Placebo oral followed by 20mg Psilocybin one hour later.

DRUG

10mg Psilocybin

Placebo oral followed by 10mg Psilocybin oral one hour later.

DRUG

5mg Psilocybin

Placebo oral followed by 5mg Psilocybin one hour later

OTHER

Placebo

Oral Placebo followed by oral Placebo one hour later

Locations (1)

Clinical Trial Unit

Basel, Canton of Basel-City, Switzerland